Back to All Collaborations

Global Alliance for TB Drug Development (TB Alliance)

Active Since: 2000

Multi-Company Partnership

Contributing to SDGs…

The Global Alliance for TB Drug Development (TB Alliance) brings together industry, NGOs, governments, foundations and more than 30 partners around the world to accelerate the discovery and development of cost-effective new medicines for TB.

PARTNER ORGANISATIONS

  • Academia or research institute

    Beijing Institute of Materia Medica

    Beijing Tuberculosis and Thoracic Tumor Research Institute

    Korea Research Institute of Chemical Technology (KRICT)

    University of Illinois

    Yonsei University, Korea

    University of Auckland, New Zealand

  • Bilateral Organisations

    Irish Aid

    UK Department for International Development (DFID)

    US Agency for International Development (USAID)

    US Food and Drug Administration (US FDA)

  • Government

    Netherlands Ministry of Foreign Affairs

    US National Institutes of Health (NIH)

  • Intergovernmental Organizations and Multilaterals

    European Commission

    European Union

    Global Health Innovative Technology (GHIT) Fund

    UNITAID

  • Pharma (Non-IPFMA Member)

    Cumbre

    Evotec

  • Private foundation or development organization

    Rockefeller Foundation

    Bill and Melinda Gates Foundation

Objectives

  • TB Alliance is a not-for-profit product development partnership (PDP) to leverage a global network of public and private partners to most efficiently advance TB drug development. A PDP builds partnerships between the public, private, academic, and philanthropic sectors to drive the development of new products for underserved markets. PDPs retain direct management oversight of their projects, though much of the laboratory and clinical work is done though external research facilities and contractors.
  • TB Alliance combines the research and development expertise of its staff with the skills and resources of its partners to harness the most promising science wherever it may exist around the world. This model minimises costs, including overhead and investments in infrastructure, while optimising scientific capability to speed up new TB drug development.

TB has surpassed HIV as the leading infectious killer of adults worldwide. In 2017, TB caused an estimated 1.3 million deaths among HIV-negative people and there were an additional 300,000 deaths from TB among HIV-positive people. Globally, the best estimate is that 10.0 million people developed TB disease in 2017. It is estimated that one-quarter of the global population has latent tuberculosis infection, of whom approximately 10% will develop active pulmonary tuberculosis disease.

Active TB attacks the respiratory system and other organs, destroying body tissue. The disease is contagious, spreading through the air by coughing, sneezing, or even talking. The current six-month standard treatment period for TB is based on four medicines that were discovered over 40 years ago. Medicines must be taken for 6 to 8 months, frequently under the direct supervision of healthcare professionals as Directly Observed Therapy– short course (DOTS). A reduced TB treatment regimen should help improve patient compliance, reduce treatment failure rates and decrease the TB-related health costs in endemic disease countries.

The Global Alliance for TB Drug Development (TB Alliance), established in 2000, brings together industry, NGOs, governments, foundations and more than 30 partners around the world to accelerate the discovery and development of cost-effective new medicines. The TB Alliance draws on the best practices and resources of the public and private sectors to accelerate the discovery and development of cost-effective new anti-TB medicines, which should shorten or simplify treatment, provide a more effective treatment of multidrug-resistant TB and improve treatment of latent TB infection.

The founders of the TB Alliance are the Bill and Melinda Gates Foundation, the Rockefeller Foundation, the US Agency for International Development (USAID), Irish Aid, the Netherlands’ Ministry of Foreign Affairs and the UK Department of International Development (DFID). Company partners have included AstraZeneca, Bayer Healthcare, Eli Lilly, GSK, Johnson and Johnson and Novartis.

The partnership functions as a virtual R&D organisation. By outsourcing medicine research and development projects, medicine compounds are moved along the development line to achieve regulatory approval and bring them to market at affordable prices for those countries experiencing the highest burden from TB. TB Alliance activities in low and middle income countries include clinical trials in Kenya, South Africa and Zambia and non-clinical or preclinical work in China and India.

Forging global partnerships, the TB Alliance has partnered with some of the world’s leading drug developers to jointly manage TB drug discovery portfolios consisting of multiple TB drug discovery programs. This approach aligns target product profiles, makes efficient use of resources, and leverages the expertise and contributions of each partner to have a significant impact on the global discovery portfolio. The TB Alliance jointly manages TB drug discovery portfolios with companies:

Bayer activities: Pre-clinical studies have shown that moxifloxacin can reduce the treatment period by two months, if it is administered in place of Isoniazid – one of the pillars of current TB treatment. The results of clinical phase-II studies support the treatment reduction potential of moxifloxacin. Moxifloxacin is currently approved in 123 countries for the treatment of acute bacterial infections but is currently not approved for the treatment of TB, including multi-drug resistant TB (MDR-TB). Moxifloxacin is currently being assessed in a large, phase-III study (REMoxTB) which may result in the registration of the first new drug approved for the treatment of drug-sensitive TB in nearly 50 years. In all studies, Bayer has made the antibiotic moxifloxacin available free of charge and in cases of positive results will also bear the costs for the approval procedures. To learn more about these trails, click here. If the data from the clinical trial is positive, TB Alliance and Bayer Healthcare will seek registration of moxifloxacin as part of a multi-drug regimen for drug-sensitive TB and work to make it widely adopted into existing TB treatment programs, and available and affordable to patients who most need it.

GSK activities: In March 2005, GlaxoSmithKline and the TB Alliance announced a joint discovery partnership to improve the treatment of TB. The TB Alliance provides funds to support TB discovery programmes at the GSK R&D facility in Tres Cantos, Spain, with GSK committed to at least matching the amount provided by the Alliance. The program broadens the worldwide TB medicine pipeline by adding several novel classes of compounds with new mechanisms of action. The joint research program consists of a mini-portfolio projects intended to yield new compounds that attack Mycobacterium tuberculosis (M.tb) on multiple levels. The mini-portfolio consists of multiple compounds/series that were identified via phenotypic or target-based screening. Special attention is dedicated to the discovery of compounds active against M.tb which are not effectively cleared by current anti-TB drugs. A shorter TB regimen is expected to improve patient compliance, increase cure rates and lower toxic side effects, thereby limiting the rise of new resistant strains. A novel TB regimen that is compatible with HIV treatments would improve TB control and help in the fight against AIDS.  In 2016, GSK and TB Alliance agreed a 5-year extension of the programme.

SDGs THE PARTNERSHIP CONTRIBUTES TO

SDG 3: Good Health and Wellbeing

  1. 3.3: Communicable Diseases & NTDs

SDG 5: Gender Equality

SDG 10: Reduced Inequalities

SDG 17: Partnerships for the Goals 

RESULTS & MILESTONES

On December 14, 2018, TB Alliance submitted its first ever New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the review and approval of the drug pretomanid, in combination with bedaquiline and linezolid (collectively known as the BPaL regimen), for the treatment of extensively drug-resistant TB and multidrug-resistant TB that is treatment-intolerant or non-responsive. This application, which has now been accepted by the FDA for Priority Review, is a major milestone for the organization.